A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)
A Phase Ib, Multi-center, Open, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ningetinib (CT053PTSA) in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Sponsor: Sunshine Lake Pharma Co., Ltd.
Terminated
Company strategy adjustment
Other terminated trials from Sunshine Lake Pharma Co., Ltd.
- Hepatitis B, Chronic · Phase PHASE1/PHASE2 · Mar 2023
- Pancreatic Cancer · Phase PHASE1 · Sep 2021
- Renal Cell Cancer Metastatic · Phase PHASE1/PHASE2 · May 2020
More terminations from Sunshine Lake Pharma Co., Ltd.
Other Acute Myeloid Leukemia (AML) trials with similar outcome
Listed as NCT03125876, this PHASE1 trial focuses on Acute Myeloid Leukemia (AML) and remains terminated or withdrawn. Sponsored by Sunshine Lake Pharma Co., Ltd., it has been updated 8 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2021 — Jul 2024 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Feb 2021 — Apr 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sunshine Lake Pharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .